Sepsis Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Technology, By Product, By Diagnostic Method, By Pathogen, and By Region, Competition

Global Sepsis Diagnostics Market has valued at USD 685.30 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.22% through 2028. Sepsis is a life-threatening medical condition that occurs when the body's response to infection becomes dysregulated, leading to widespread inflammation and potentially causing multiple organ dysfunction or failure. It is a severe and rapidly progressing condition that requires immediate medical attention and treatment. Sepsis typically begins with an infection, which can be caused by bacteria, viruses, fungi, or parasites. The infection can originate from various sources, such as a wound, urinary tract infection, respiratory infection, or an infected surgical site. When the body detects an infection, the immune system responds by releasing chemicals to fight off the invading pathogens. This immune response is a natural defense mechanism to contain and eliminate the infection.

In sepsis, the immune response becomes dysregulated or overactive. Instead of effectively targeting the infection, the immune system goes into overdrive, releasing excessive amounts of inflammatory chemicals into the bloodstream. The increasing prevalence of sepsis cases worldwide has been a significant driver for the sepsis diagnostics market. Sepsis is a critical condition that requires early and accurate diagnosis for effective treatment. There has been a growing awareness among healthcare professionals and the general public about sepsis and its potential severity. This awareness has led to increased testing and diagnosis. Continuous advancements in diagnostic technologies, such as molecular diagnostics, immunoassays, and blood culture systems, have improved the accuracy and speed of sepsis diagnosis. These technological innovations have expanded the market by providing more reliable and efficient diagnostic tools. The aging global population is more susceptible to infections and sepsis. As the elderly population continues to grow, the demand for sepsis diagnostics is expected to rise.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 571.03 Million
Market Size 2028	USD 874.84 Million
CAGR 2023-2028	7.22%
Fastest Growing Segment	Molecular Diagnostics
Largest Market	North America

Advancements in Sepsis Diagnostic Technologies

Advancements in sepsis diagnostic technologies have been crucial in improving the accuracy, speed, and efficiency of sepsis diagnosis. These innovations enable healthcare professionals to identify sepsis earlier and initiate timely treatment, which is critical for patient outcomes. Polymerase Chain Reaction (PCR) technology allows for the rapid detection of specific microbial DNA or RNA, enabling the identification of sepsis-causing pathogens with high accuracy. Next-Generation Sequencing (NGS) technology has the potential to identify a wide range of pathogens simultaneously and can be used to detect both known and novel pathogens responsible for sepsis. Automated Blood Culture Systems automate the process of detecting bacterial or fungal growth in blood samples, providing faster results than traditional manual methods. Blood Culture Bottles with Antibiotic Neutralization containers help overcome the inhibitory effects of antibiotics in the bloodstream, enhancing the recovery of microorganisms from septic patients. Immunoassays can measure the levels of specific cytokines, such as procalcitonin (PCT) and C-reactive protein (CRP), which are used as biomarkers to assess the severity of sepsis. Lateral Flow Assays rapid tests can detect sepsis-related biomarkers at the point of care, allowing for quick diagnosis and treatment decisions. Analyzing the gene expression patterns of the host's immune response can help identify sepsis and differentiate it from other inflammatory conditions. MicroRNA profiles have shown promise as diagnostic markers for sepsis.

POCT (Point-of-Care Testing) devices with biosensors can detect sepsis-related biomarkers in blood samples, providing rapid results at the bedside. Microfluidic systems enable the efficient processing of small sample volumes and can be integrated into portable diagnostic devices for sepsis detection. AI and machine learning algorithms have been applied to sepsis diagnostics. They can analyze clinical data, laboratory results, and vital signs to identify early signs of sepsis, aiding in early intervention. Advanced imaging modalities like ultrasound, CT scans, and MRI can help identify signs of infection, such as abscesses or organ damage, aiding in the diagnosis and monitoring of sepsis. Multiplex assays can simultaneously measure multiple biomarkers associated with sepsis, providing a more comprehensive diagnostic profile. Advanced sequencing technologies can directly sequence bacterial DNA in clinical samples, allowing for the rapid identification of specific pathogens causing sepsis. Telemedicine platforms and remote monitoring technologies have become more important during the COVID-19 pandemic, enabling healthcare providers to monitor patients remotely and detect early signs of sepsis. This factor will help in the development of Global Sepsis Diagnostics Market.

Rising cases of Sepsis

The global incidence of sepsis has been on the rise. This can be attributed to factors such as an aging population, a growing number of people with chronic illnesses, and the emergence of antibiotic-resistant pathogens. As more individuals are at risk of sepsis, the need for early and accurate diagnosis becomes crucial. There has been a growing awareness among the public and healthcare professionals about the signs and symptoms of sepsis. Increased awareness leads to more people seeking medical attention when they suspect sepsis, resulting in higher diagnostic demand. Advances in medical science and technology have improved the understanding of sepsis, its pathophysiology, and the importance of early diagnosis. Healthcare providers are more inclined to use diagnostic tools to confirm or rule out sepsis quickly.

Regulatory bodies and healthcare organizations have placed an increased emphasis on the early detection and management of sepsis. This has led to the development and adoption of guidelines that recommend the use of diagnostic tests to identify sepsis promptly. The demand for point-of-care testing for sepsis has grown due to its ability to provide rapid results at the patient's bedside. This is especially valuable in emergency departments and critical care settings, where timely diagnosis is critical. Advances in sepsis treatment, such as new antibiotics and therapies, have underscored the importance of accurate diagnosis to tailor treatment regimens to the specific pathogens causing the infection. Improvements in healthcare infrastructure and laboratory facilities have made it easier to perform sepsis diagnostic tests, even in resource-limited settings. The healthcare community has been working on infection control and prevention measures to reduce the incidence of sepsis, but early detection remains essential. Effective prevention and early diagnosis complement each other in reducing sepsis cases. Events like the COVID-19 pandemic have highlighted the critical role of diagnostics in managing infectious diseases, including sepsis. Investments in healthcare infrastructure and diagnostics have been made in response to such crises. This factor will pace up the demand of Global Sepsis Diagnostics Market.

Increasing Incidence of Hospital-Acquired Infections

Hospital-acquired infections are infections that patients acquire during their stay in a healthcare facility, including hospitals and nursing homes. These infections can often progress to sepsis if not promptly detected and treated. Patients in healthcare settings are at an elevated risk of developing infections due to factors such as weakened immune systems, surgical procedures, invasive medical devices (e.g., catheters), and prolonged hospital stays. If these infections are not promptly identified and treated, they can progress to sepsis. Early detection of HAIs and their potential progression to sepsis is critical for patient safety. Sepsis diagnostics play a crucial role in identifying patients at risk of developing sepsis, allowing for timely intervention and treatment. Healthcare facilities implement rigorous infection control measures to reduce the incidence of HAIs. Part of these measures includes monitoring and early detection of infections. Sepsis diagnostics aid in this monitoring process, helping to prevent the development of sepsis. In some cases, healthcare facilities may experience outbreaks of specific infections, such as methicillin-resistant Staphylococcus aureus (MRSA) or Clostridium difficile (C. diff) infections. Rapid and accurate diagnosis of these outbreaks is essential to contain the spread and prevent sepsis cases.

Healthcare facilities are subject to regulatory requirements and guidelines that mandate the monitoring and reporting of HAIs. Compliance with these regulations often involves using sepsis diagnostics to track infection rates and outcomes. Hospitals and healthcare providers prioritize patient safety and strive to improve clinical outcomes. Timely diagnosis and management of sepsis cases resulting from HAIs are key components of these efforts. Sepsis resulting from HAIs can significantly increase healthcare costs due to prolonged hospital stays, intensive care treatment, and additional medical interventions. Timely diagnosis and intervention can help reduce the economic burden on healthcare systems. Patient advocacy groups and organizations have raised awareness about the risks of HAIs and the importance of infection control. This has led to increased scrutiny and emphasis on the need for effective sepsis diagnostics in healthcare settings. This factor will accelerate the demand of Global Sepsis Diagnostics Market.

Key Market Challenges

Generic Competition

When generic alternatives become available for diagnostic tests, they often come at a lower price than branded products. This can lead to price erosion in the market, putting pressure on the revenues and profit margins of companies manufacturing branded sepsis diagnostic tests. Generic manufacturers can capture a significant share of the market by offering cost-effective alternatives to branded sepsis diagnostic tests. This competition can affect the market share of existing diagnostic companies and potentially limit their growth prospects. Diagnostic companies typically invest substantial resources in research and development to create innovative sepsis diagnostic technologies. Once patents and exclusivity rights expire, generic manufacturers can legally produce and market similar diagnostic tests, reducing the competitive advantage of the original innovator. To compete with generics, branded sepsis diagnostic companies may need to adjust their pricing strategies, which can impact their profitability. Lowering prices to remain competitive may be necessary, but it can affect the overall market dynamics. The presence of generic competition can deter companies from investing in research and development for new and improved sepsis diagnostic technologies. This can slow down innovation in the field and limit the introduction of advanced diagnostic tools. While generic diagnostic tests aim to provide cost-effective alternatives, there may be concerns about the quality, reliability, and accuracy of these products. Regulatory bodies play a crucial role in ensuring that generic tests meet the necessary quality and safety standards.

Adverse Effects

Some diagnostic procedures used in sepsis diagnostics, such as blood culture collection, may be invasive and carry a risk of discomfort, infection, or other complications. While these procedures are necessary for accurate diagnosis, healthcare providers should take appropriate precautions to minimize risks. Frequent blood drawers for diagnostic tests can lead to potential discomfort and complications, especially in critically ill patients. The risks associated with blood collection, such as hematoma formation or infection at the puncture site, should be managed effectively. Diagnostic testing, especially in an intensive care or emergency setting, can cause anxiety and stress for patients. It is essential for healthcare providers to communicate effectively and provide emotional support to patients undergoing sepsis diagnostics. In some cases, there may be a risk of overusing diagnostic tests for sepsis, which can lead to unnecessary discomfort and costs for patients. Effective clinical guidelines and decision support tools are essential to ensure appropriate test utilization. Following diagnosis, patients with sepsis require continuous monitoring and management. While this is not an adverse effect per se, it is a critical aspect of sepsis care to prevent complications and optimize patient outcomes.

Key Market Trends

Biomarker Discovery

Biomarkers provide a more precise and specific way to identify sepsis compared to traditional clinical signs and symptoms. This can lead to earlier and more accurate diagnosis, allowing for timely intervention. Sepsis can present with symptoms that overlap with other medical conditions. Biomarkers that are specific to sepsis help differentiate it from non-septic conditions, reducing the risk of misdiagnosis. Certain biomarkers can indicate the severity of sepsis, helping healthcare providers assess the level of organ dysfunction and tailor treatment accordingly. Biomarkers can be used to monitor the progression of sepsis, allowing for adjustments in treatment plans as needed. Biomarker discovery contributes to the trend of personalized medicine in sepsis care. Tailoring treatment based on a patient's specific biomarker profile can lead to more effective and targeted interventions. The identification of novel biomarkers for sepsis has been a focus of research and development efforts. This has led to the introduction of new diagnostic tests and products onto the market. Multiplex assays that measure multiple biomarkers simultaneously have gained popularity. These panels can provide a more comprehensive diagnostic profile and improve the accuracy of sepsis diagnosis. Research has shown promise in using microRNA profiles as diagnostic markers for sepsis. MicroRNA biomarkers can provide valuable information about the host response to infection.

Segmental Insights

Technology Insights

In 2022, the Global Sepsis Diagnostics Market dominated by microbiology technology segment and is predicted to continue expanding over the coming years. This might be linked to the fact that the use of culture medium tests in microbiology technology enables precise detection and identification of bacteria for sepsis diagnosis. New strategic initiatives by important players are also fuelling the segment's expansion. For instance, in April 2019, BD introduced its brand-new BD BACTEC platelet quality control media, which aids in the detection and reduction of sepsis among patients getting platelet transfusions.

Product Insights

In 2022, the Global Sepsis Diagnostics Market dominated by blood culture media product segment and is predicted to continue expanding over the coming years. Over the forecast period, the segment is anticipated to keep up its lead. This is because clinicians view blood cultures as the most practical and economical testing method. The global market has been divided into three product categories based on type: instruments, blood culture media, and test kits & reagents. In a study on sepsis patients in Thailand, it was found that the Septifast assay, a PCR-based technique, performed better as a diagnostic tool than Blood Culture.

Diagnostic Method Insights

In 2022, the Global Sepsis Diagnostics Market dominated by conventional diagnostics segment and is predicted to continue expanding over the coming years. The traditional approach to diagnosing sepsis depends on the knowledge of healthcare professionals to assess the patient's clinical presentation and decipher lab and imaging results. Sepsis must be quickly identified and treated to enhance patient outcomes.

Pathogen Insights

In 2022, the Global Sepsis Diagnostics Market largest share was dominated by bacterial sepsis segment in the forecast period and is predicted to continue expanding over the coming years. Due to the increase in surgical operations, the growth in hospital-transmitted infections, and the rise in cases of bacterial sepsis. Bacterial sepsis is the most frequent form, with 62.2% of patients having gram-negative bacteria and 46.8% having gram-positive bacteria, according to a report released by SAGE Journals in January 2019. The market is divided into categories for bacterial sepsis, fungal sepsis, and other pathogen-based sepsis. Over the course of the projection period, it is predicted that the gram-negative bacteria sub-segment will lead the market in the bacterial sepsis segment.

Regional Insights

The North America region dominates the Global Sepsis Diagnostics Market in 2022. Throughout the predicted period, it is anticipated that the region would keep up its lead. This development can be linked to the region's increased use of advanced diagnostic tools due to the presence of a strong healthcare infrastructure. Additionally, the market expansion in this area is being fueled by the substantial presence of important competitors and a favorable reimbursement system. Additionally, it is anticipated that the rising prevalence of infectious illnesses and sepsis will increase the need for cutting-edge diagnostic methods.

Key Market Players

• Abbott Laboratories Inc.

• DiaSorin SpA

• Becton, Dickinson, and Company

• BioMerieux Inc.

• F. Hoffmann-La Roche AG

• Danaher Corporation

• Thermo Fisher Scientific Inc

• Siemens Healthineers AG

• Seegene, Inc.

• Roche Diagnostics Corporation

Report Scope:

In this report, the Global Sepsis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Sepsis Diagnostics Market, By Technology:

• Molecular Diagnostics
• Microbiology
• Immunoassay
• Other Technologies

Sepsis Diagnostics Market, By Product:

• Instruments
• Assays and Reagents
• Other Products

Sepsis Diagnostics Market, By Diagnostic Method:

• Conventional Diagnostics
• Automated Diagnostics

Sepsis Diagnostics Market, By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Other Pathogens

Global Sepsis Diagnostics Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Sepsis Diagnostics Market.

Available Customizations:

• Global Sepsis Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).